SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Medical Oncology Consultation — Edward W. Brooke
| Patient | Edward W. Brooke |
|---|
| Date of birth | 1942-10-26 |
|---|
| Identifiers | MRN HR-ML014-SYN; SSN (made up) 000-14-5063 |
|---|
| Document date | 2026-02-10 |
|---|
| Author | Mei-Ling Cho, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
Man of 83 with stage IIA, hormone receptor-positive, HER2-negative right breast cancer, fourteen weeks after bilateral mastectomy and right axillary dissection, on tamoxifen for eleven weeks, started at another hospital. Please take over his adjuvant endocrine therapy, confirm the adjuvant plan, and arrange germline genetic testing. [S]
Urgency: Routine, within four weeks. [S]
Questions for the consultant:
- Is tamoxifen the right adjuvant endocrine therapy for him, and for how long?
- Is any other adjuvant treatment, such as chemotherapy or radiation, indicated now?
- Which germline test should he have, and what would a result mean for him and his relatives?
- How should tamoxifen safety be monitored at his age, and which medicines should he avoid?
- What surveillance does he need after bilateral mastectomy, and what should be done about his bone health?
History of Present Illness
Mr. Brooke is seen at the request of Dr. Bellamy to take over his breast cancer care. He noticed discomfort in his right breast, which he dismissed for a time, before imaging and biopsy showed cancer; he says he did not know men could get breast cancer. He had a bilateral mastectomy and right axillary dissection at another hospital about four months ago, and started tamoxifen four weeks later. He has taken it daily for fifteen weeks with mild night hot flashes and no other effects. He has no bone pain, cough, headache, or weight loss. He is independent, walks most days, and has no history of blood clots, stroke, or liver disease. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Edward William Brooke III was born in Washington, D.C., on October 26, 1919. [D]
- Brooke was elected attorney general of Massachusetts in 1962 and re-elected in 1964, and in 1966 became the first African American elected to the U.S. Senate by popular vote; he served as a Republican senator from Massachusetts from January 3, 1967, to January 3, 1979. [D]
- In a CNN interview aired on June 11, 2003, Brooke said that in September 2002 he felt discomfort in his right breast, which he dismissed as aging, possible muscle strain, or gas; that he then had a mammogram, a sonogram, and a needle biopsy, which found a malignant tumor; that his breasts had never before been examined by a doctor; and that he had not thought men got breast cancer. [D]
- In the same interview Brooke said he had to be operated on for breast cancer, that the cancer had spread to his lymph nodes, and that all of the lymph nodes on his right side were removed. [D]
- An Associated Press report of June 11, 2003, said that Brooke, 83, had been diagnosed with breast cancer in September, had a double mastectomy, and was free of the cancer, and that he was encouraging men to examine themselves and urging insurers to cover mammograms for men. [D]
- In the 2003 interview Brooke described himself as not a smoker or a drinker and said he exercised and ate fairly good food. [D]
2 later historical claims are omitted because they describe events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Tamoxifen 20 mg oral tablet, one tablet by mouth once daily (adjuvant endocrine therapy, planned for at least five years) | One tablet once daily | Oral route | 2025-10-28 | active | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2026-02-10 | active | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Invasive ductal carcinoma of the right male breast, central (retroareolar) portion, stage IIA (pT1c pN1a M0), grade 2, ER positive, PR positive, HER2 negative; treated by bilateral mastectomy and right axillary lymph node dissection; on adjuvant tamoxifen; synthetic modern detail linked to his publicly disclosed breast cancer | active | confirmed |
C50.121 | S — Synthetic tumor size, grade, receptor status, and stage; the diagnosis, the right side, the operation, and the spread to lymph nodes are from his public account (D). |
| Estrogen receptor-positive status of the breast cancer | active | confirmed |
Z17.0 | S — Synthetic receptor result; his tumor biology was not made public. |
| Long-term use of tamoxifen, with safety monitoring (venous thromboembolism, mood, hot flashes, sexual side effects, adherence) and bone health review | active | confirmed |
Z79.810 | S — Synthetic adjuvant therapy in the modern episode. |
| Absence of both breasts after bilateral mastectomy | active | confirmed |
Z90.13 | S — The double mastectomy is reported publicly (D); the coding is synthetic. |
Physical Exam
Vital signs recorded on 2026-02-10; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|
| General | Well |
| Chest wall | Healed transverse mastectomy scars on both sides; no nodule or skin change |
| Lymph nodes | No axillary, supraclavicular, or cervical nodes on either side |
| Extremities | Upper arm circumference 31 cm on both sides; no calf swelling or tenderness |
| Abdomen | Soft; liver not enlarged |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 2026-02-10 | DXA Femur [T-score] Bone density | -1.2 | {T-score} | -1.0 or higher is normal; -2.5 or lower is osteoporosis | Low | S |
| 2026-02-10 | DXA Lumbar spine [T-score] Bone density | -0.4 | {T-score} | -1.0 or higher is normal; -2.5 or lower is osteoporosis | Normal | S |
| 2026-02-10 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | | | S |
Assessment
- Right breast cancer, pT1c pN1a M0, stage IIA, ER and PR positive, HER2 negative, grade 2 (C50.121). Breast cancer in men is less common than in women but is biologically similar, and most cases are hormone receptor-positive, as his is. With one small nodal metastasis, a strongly ER-positive grade 2 tumor, and his age of 83, endocrine therapy gives most of the benefit. The added gain from chemotherapy would be small and its harms greater at his age. Radiation after mastectomy for one involved node is a choice with a small gain in local control; with clear margins and no extranodal spread, omitting it is reasonable, and I agree with the decision made after surgery. No staging scans are needed without symptoms. [S]
- Adjuvant tamoxifen (Z79.810). Tamoxifen is the preferred adjuvant endocrine therapy for men. An aromatase inhibitor alone does not suppress estrogen adequately in men and is not recommended; it would be used only with a GnRH agonist if tamoxifen could not be taken. His mild hot flashes are common in men on tamoxifen. The main serious risk at his age is venous thromboembolism; he has no history of clots. [S]
- Germline genetic testing. Genetic counseling and germline testing should be offered to every man with breast cancer, whatever his age or family history. BRCA2 is the gene most often involved; a pathogenic variant would raise his risk of prostate and pancreatic cancer and would mean his relatives should be offered testing. [S]
- Bone health. Low bone mass at the femoral neck with mild vitamin D insufficiency. His fracture risk does not call for a bone drug. Bone-modifying drugs should not be given to prevent recurrence of early breast cancer in men, but can be used if osteoporosis develops. [S]
Data reviewed: Outside imaging reports (bilateral diagnostic mammography and bilateral breast and axillary ultrasound), biopsy and surgical pathology with ER, PR, HER2, and Ki-67; the first-visit blood count, chemistry, and 25-hydroxyvitamin D; and the DXA scan from this morning (femoral neck T-score -1.2, lumbar spine -0.4). [S]
Plan of Treatment
- Continue tamoxifen 20 mg daily for an initial five years; at five years, if he tolerates it, discuss five more years given the involved node. Do not switch to an aromatase inhibitor alone. [S]
- No chemotherapy and no radiation now. [S]
- Genetic counseling and a germline multigene panel (BRCA2, BRCA1, PALB2, CHEK2, ATM, and others), sent today; if a variant is found, a letter for relatives offering them testing, and prostate and pancreatic screening for him. [S]
- Tamoxifen safety at each visit: symptoms of leg or lung clots, mood, hot flashes, sexual side effects such as lower libido or erectile problems, and adherence; avoid paroxetine, fluoxetine, and bupropion, which block its activation; report any change in vision. [S]
- Surveillance: history and examination of both sides of the chest wall and both axillae every 3 to 6 months for 3 years, then every 6 to 12 months to 5 years, then yearly. No mammography, because both breasts were removed, and no routine blood tests, tumor markers, or scans without symptoms. [S]
- Bone health: vitamin D 1000 units daily with a recheck in three months, calcium from food, weight-bearing exercise, and DXA every two years. [S]
- Lymphedema risk reduction for the right arm and a written survivorship care plan within the first year. [S]
- Discussed with Dr. Bellamy today. The patient agrees with the plan. He asked that his diagnosis be kept private for now, and that wish is recorded. [S]
- Follow-up: Medical oncology every six months and at five years for the decision on extending tamoxifen. Genetic counseling for the germline result. Primary care continues tamoxifen safety checks, distress screening, bone health, and survivorship visits every three months. [S]